713 related articles for article (PubMed ID: 26077642)
1. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinase inhibition as a cancer therapeutic strategy.
D'Arcy P; Wang X; Linder S
Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
[TBL] [Abstract][Full Text] [Related]
4. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
Pal A; Young MA; Donato NJ
Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: translational potential of deubiquitinases as drug targets.
D'Arcy P; Linder S
Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788
[TBL] [Abstract][Full Text] [Related]
6. Proteasome deubiquitinases as novel targets for cancer therapy.
D'Arcy P; Linder S
Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
[TBL] [Abstract][Full Text] [Related]
7. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
9. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
10. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitinases in cancer.
Wei R; Liu X; Yu W; Yang T; Cai W; Liu J; Huang X; Xu GT; Zhao S; Yang J; Liu S
Oncotarget; 2015 May; 6(15):12872-89. PubMed ID: 25972356
[TBL] [Abstract][Full Text] [Related]
12. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinating enzymes as therapeutic targets in cancer.
Lim KH; Baek KH
Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S
Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145
[TBL] [Abstract][Full Text] [Related]
15. Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.
Chen X; Yang Q; Xiao L; Tang D; Dou QP; Liu J
Cancer Metastasis Rev; 2017 Dec; 36(4):655-668. PubMed ID: 29039082
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinases in cancer: new functions and therapeutic options.
Fraile JM; Quesada V; Rodríguez D; Freije JM; López-Otín C
Oncogene; 2012 May; 31(19):2373-88. PubMed ID: 21996736
[TBL] [Abstract][Full Text] [Related]
18. Targeting Deubiquitinases in Cancer.
Bednash JS; Mallampalli RK
Methods Mol Biol; 2018; 1731():295-305. PubMed ID: 29318562
[TBL] [Abstract][Full Text] [Related]
19. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J
Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524
[TBL] [Abstract][Full Text] [Related]
20. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
